Epirus Biopharmaceuticals, Inc. (NASDAQ:EPRS)

CAPS Rating: 3 out of 5

A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.


Player Avatar zzlangerhans (99.85) Submitted: 8/4/2011 6:01:41 PM : Outperform Start Price: $117.00 EPRS Score: -57.69

Ok, I was wrong. Stocklasar, charlie17, Fungusface, Monkeynutz and the whole gang schooled me on this stock. Zalicus is certainly destined for greatness. Exalgo revenues are blowing the roof off exactly as predicted, and the Synavive trial is a certain success. Thanks for showing me the light, guys! See you at $50!

Report this Post 3 Replies
Member Avatar London2485 (65.78) Submitted: 8/5/2011 8:40:36 PM
Recs: 0

Wait a minute..... does something smell in here?

Member Avatar goldminingXpert (29.65) Submitted: 8/31/2011 10:10:45 AM
Recs: 0

Wait, what? Doesn't this stock still stink?

Member Avatar zzlangerhans (99.85) Submitted: 9/2/2011 12:55:00 PM
Recs: 0

It actually blows. I was trying to catch a little rebound but underestimated the frailty of the Zalicus longs. It seems they bark harder than they bite.

Featured Broker Partners